BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • abkaufman.jpg
    Donald S. Kaufman, M.D.
    Clinical Professor of Medicine; Director of Bertucci Center for Genitourinary Cancers
    Harvard Medical School and Massachusetts General Hospital
    Donald S. Kaufman, M.D. is a Clinical Professor of Medicine, Harvard Medical School, and Director of the Claire and John Bertucci Center for Genitourinary Cancers at Massachusetts General Hospital.

    Dr. Kaufman’s research, teaching and clinical interests are all in the area of genitourinary oncology, primarily in the search for more effective treatments for bladder and prostate cancers. His research in bladder cancer is focused on improving treatment options of this common and highly malignant tumor while attempting to improve quality of life by preserving the patient’s native bladder.The Claire and John Bertucci Center for Genitourinary Cancers is multidisciplinary in both its clinical and research activities. Dr. Kaufman’s research interests include studies of bladder preservation in the treatment of muscle-invasive bladder cancer and innovative chemotherapy in the treatment of advanced bladder cancer. The current MGH bladder preservation protocol, a randomized phase II study combining innovative chemotherapy and radiation treatment, opened for accrual in November 2003 with Drs. Kaufman and William U. Shipley as collaborating investigators. Dr. Kaufman is the Principal Investigator for several current research protocols in the treatment of bladder cancer including protocols originating at the Massachusetts General Hospital, in the Dana-Farber Partners Joint Venture in Cancer Care, and in national consortia of teaching hospitals devoted to this effort.Dr. Kaufman and his colleagues continue to develop and refine the use of limited surgery, chemotherapy, and radiation in the management of muscle-invasive bladder cancer including: long-term cancer outcome of completed prospective studies; long-term quality of life outcome for treated patients with conserved bladders; outcome for patients with retained bladders who experience superficial bladder relapses; and planning of translational studies in conjunction with bladder preservation.Dr. Kaufman received his A.B. from Harvard University and his M.D. from Boston University School of Medicine.
    Click here for more information.